| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Trimyristin does not have a specific molecular target in the context of drug action; rather, it functions as a nutritional lipid and a metabolic substrate. As a triglyceride, it is hydrolyzed by lipases to release myristic acid, which can be utilized as an energy source or incorporated into cellular lipids. Myristic acid is a saturated fatty acid that can be used for the synthesis of other lipids and for protein myristoylation, a process that is important for the function of many proteins. In research, trimyristin is employed as a model compound in the study of lipid hydrolysis and transesterification reactions.
|
|---|---|
| ln Vitro |
In vitro, trimyristin is used as a substrate in studies of lipid metabolism and digestion. It is hydrolyzed by pancreatic lipase and other esterases to release myristic acid and glycerol. Cell-based assays can be used to study the uptake and metabolism of trimyristin or its hydrolysis products. For example, cultured adipocytes or hepatocytes can be treated with trimyristin or myristic acid, and the effects on lipid accumulation, gene expression, and cellular signaling can be measured. The compound's effects on cell viability and proliferation can also be assessed.
|
| ln Vivo |
In vivo, trimyristin is used as a dietary lipid and has been studied for its biological effects. As a source of myristic acid, trimyristin may influence lipid metabolism, immune function, and other physiological processes. It is used as a component of research diets to study the effects of saturated fatty acids on metabolism and health. The compound is also used in the food, cosmetic, and pharmaceutical industries as an excipient.
|
| Enzyme Assay |
In vitro enzyme or receptor binding (non-cell) assays for trimyristin are not typically performed, as it is not a direct enzyme inhibitor or receptor ligand. However, its hydrolysis by lipases can be studied using in vitro enzymatic assays. For example, pancreatic lipase can be incubated with trimyristin in the presence of bile salts, and the release of fatty acids can be measured by titration or using a pH-stat method. These assays are used to characterize the enzymatic hydrolysis of triglycerides and to study the effects of various factors on lipase activity.
|
| Cell Assay |
In vitro cell-based assays for trimyristin are performed using various cell lines to study its effects on cellular metabolism and function. Adipocytes, hepatocytes, or intestinal epithelial cells can be treated with trimyristin or its hydrolysis products. The uptake and metabolism of myristic acid can be traced using radiolabeled or fluorescently labeled compounds. The effects on lipid accumulation, gene expression, and inflammatory responses are measured. Cell viability and proliferation assays can also be performed to assess any potential cytotoxic or proliferative effects.
|
| Animal Protocol |
In vivo animal experiments for trimyristin are conducted using rodent models to study its metabolic effects and potential health benefits. Animals are fed a diet containing trimyristin or a control diet, and various parameters are measured, including body weight, food intake, serum lipid levels, and tissue lipid content. The compound's effects on lipid metabolism, insulin sensitivity, and inflammatory markers are assessed. These studies help to understand the role of dietary lipids in health and disease.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of trimyristin are typical of a long-chain triglyceride. After oral administration, it is hydrolyzed in the gastrointestinal tract by lipases to release myristic acid and glycerol. Myristic acid is absorbed, incorporated into chylomicrons, and transported via the lymphatic system to the bloodstream. The compound has a molecular weight of 723.16 and a molecular formula of C45H86O6. It is a white to light beige powder and should be stored at -20°C. The compound is soluble in organic solvents but practically insoluble in water.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for trimyristin indicate that it is generally recognized as safe (GRAS) for use in food and cosmetics. As a naturally occurring triglyceride, it has a low inherent toxicity. Oral administration of trimyristin is well-tolerated, and no significant adverse effects have been reported at typical dietary levels. It is not considered genotoxic, carcinogenic, or teratogenic. High doses may cause gastrointestinal discomfort.
|
| References | |
| Additional Infomation |
Trimyristic acid glyceride is a triglyceride obtained by acylation of the three hydroxyl groups of glycerol with myristic acid (tetradecanoic acid). It is both a triglyceride and a tetradecanoic acid ester. Trimyristic acid glyceride has been reported to exist in Horsfieldia glabra, Staudtia kamerunensis, and other organisms with relevant data. Trimyristic acid glyceride is a metabolite found in or produced by Saccharomyces cerevisiae.
Other information: Trimyristin is a naturally occurring triglyceride found in nutmeg, palm oil, and coconut oil. It is used as an emollient, thickening agent, and lipid source in various industries. In research, it is used as a model compound for studying lipid metabolism and as a reference standard. Its CAS number is 555-45-3." |
| Molecular Formula |
C45H86O6
|
|---|---|
| Molecular Weight |
723.177
|
| Exact Mass |
722.642
|
| CAS # |
555-45-3
|
| Related CAS # |
Trimyristin--d15;1219804-94-0
|
| PubChem CID |
11148
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
703.5±27.0 °C at 760 mmHg
|
| Melting Point |
56-57 °C(lit.)
|
| Flash Point |
270.9±23.8 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.464
|
| LogP |
18.89
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
44
|
| Heavy Atom Count |
51
|
| Complexity |
711
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DUXYWXYOBMKGIN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C45H86O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-43(46)49-40-42(51-45(48)39-36-33-30-27-24-21-18-15-12-9-6-3)41-50-44(47)38-35-32-29-26-23-20-17-14-11-8-5-2/h42H,4-41H2,1-3H3
|
| Chemical Name |
2,3-di(tetradecanoyloxy)propyl tetradecanoate
|
| Synonyms |
NSC 4062; Myristic Acid Triglyceride; Trimyristin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3828 mL | 6.9139 mL | 13.8278 mL | |
| 5 mM | 0.2766 mL | 1.3828 mL | 2.7656 mL | |
| 10 mM | 0.1383 mL | 0.6914 mL | 1.3828 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
